NCT06087458 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
| NCT ID | NCT06087458 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Perceive Biotherapeutics, Inc. |
| Condition | Age-Related Macular Degeneration |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-06-21 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2023-06-21 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.
Eligibility Criteria
Inclusion Criteria: * Are ≥60 years of age at the time of consent. * Are willing and able to understand and provide written informed consent. * Are willing and able to return for scheduled treatment and follow-up examinations. * Are able to undergo ETDRS BCDVA testing and ophthalmic imaging. * Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes. * Absence of signs of non-exudative MNV. * Additional Ocular Inclusion Criteria for both eyes. * Meet certain genotype criteria for risk of AMD. Exclusion Criteria: * Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study. * Additional Systemic, Ocular, and Genetic Exclusion Criteria.
Contact & Investigator
Anne Fung, MD
STUDY DIRECTOR
Perceive Biotherapeutics, Inc.
Frequently Asked Questions
Who can join the NCT06087458 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Age-Related Macular Degeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06087458 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06087458 currently recruiting?
Yes, NCT06087458 is actively recruiting participants. Contact the research team at Voy101clinical@perceivebio.com for enrollment information.
Where is the NCT06087458 trial being conducted?
This trial is being conducted at Scottsdale, United States, Encino, United States, Sacramento, United States, San Diego, United States and 7 additional locations.
Who is sponsoring the NCT06087458 clinical trial?
NCT06087458 is sponsored by Perceive Biotherapeutics, Inc.. The principal investigator is Anne Fung, MD at Perceive Biotherapeutics, Inc.. The trial plans to enroll 60 participants.